MiR-361-5p Regulates Ovarian Cancer Cell Proliferation and Apoptosis by Targeting TRAF3

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2021 Jan 27

PMID 33500694

Citations 4

Authors

Jianmei Ling

Panwen He

Affiliations

Soon will be listed here.

Abstract

An increasing body of evidence has demonstrated that the abnormal expression of microRNAs (miRNAs) participate in the development and progression of ovarian cancer. miR-361-5p has been reported to serve as a tumor suppressor or oncogene in a number of different human cancer types. In the current study, it was indicated that miR-361-5p was highly expressed in ovarian cancer tissues. Compared with human ovarian epithelial cells HOSEpiC, miR-361-5p was upregulated in ovarian cancer cell lines, including in ES-2 and SKOV3 cells. The binding sites between TNF receptor-associated factor 3 (TRAF3; a member of the TRAF family of cytoplasmic adaptor proteins) and miR-361-5p were predicted using TargetScan, and a dual luciferase reporter gene assay verified the result. Subsequently, a reverse transcription-quantitative PCR assay and western blot assay indicated that TRAF3 was downregulated in ovarian cancer tissues and cell lines. It was demonstrated that miR-361-5p inhibitor significantly reduced the viability of SKOV3 cells and induced apoptosis. However, all changes were reversed by TRAF3 silencing. Furthermore, it was demonstrated that miR-361-5p inhibitor decreased the expression of p-p65 in SKOV3 cells, indicating the inhibition of the NF-kB signaling pathway. In conclusion, miR-361-5p may regulate the proliferation and apoptosis of ovarian cancer cells by targeting TRAF3. Therefore, targeting miR-361-5p may exhibit therapeutic potential in the treatment of ovarian cancer.

Citing Articles

miR-361-5p regulates SLC25A24 to maintain mitochondrial function and alleviate granulosa cell dysfunction in diminished ovarian reserve.

Xu J, Jia Y J Assist Reprod Genet. 2025; .

PMID: 39810070 DOI: 10.1007/s10815-024-03349-6.

The modulation of immune cell death in connection to microRNAs and natural products.

Chuang Y, Yen C, Tang J, Chang F, Tsai Y, Wu K Front Immunol. 2025; 15:1425602.

PMID: 39759512 PMC: 11695430. DOI: 10.3389/fimmu.2024.1425602.

Development of a TLR-Based Model That Can Predict Prognosis, Tumor Microenvironment, and Drug Response for Esophageal Squamous Cell Carcinoma.

Cheng T, Huang X, Yang H, Gu J, Lu C, Zhan C Biochem Genet. 2024; 62(5):3740-3760.

PMID: 38206423 DOI: 10.1007/s10528-023-10629-w.

The complement C3a-C3aR and C5a-C5aR pathways promote viability and inflammation of human retinal pigment epithelium cells by targeting NF-κB signaling.

Luo S, Xu H, Gong X, Shen J, Chen X, Wu Z Exp Ther Med. 2022; 24(2):493.

PMID: 35837068 PMC: 9257899. DOI: 10.3892/etm.2022.11420.

Circ_0061140 Contributes to the Malignant Progression in Ovarian Cancer Cells by Mediating the RAB1A Level Through Sponging miR-361-5p.

Zhang Y, Di Q, Chen J, Chang M, Ma Y, Yu J Biochem Genet. 2022; 60(6):1946-1962.

PMID: 35181843 DOI: 10.1007/s10528-022-10200-z.

References

Wang Q, Liu N, Yang X, Tu L, Zhang X . Small RNA-mediated responses to low- and high-temperature stresses in cotton. Sci Rep. 2016; 6:35558. PMC: 5067717. DOI: 10.1038/srep35558. View

Zhu C, Gao G . miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator. Asian Pac J Cancer Prev. 2014; 15(20):8595-601. DOI: 10.7314/apjcp.2014.15.20.8595. View

Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L . MiR-361-5p acts as a tumor suppressor in prostate cancer by targeting signal transducer and activator of transcription-6(STAT6). Biochem Biophys Res Commun. 2014; 445(1):151-6. DOI: 10.1016/j.bbrc.2014.01.140. View

Xie H, Huan W, Han J, Ren W, Yang L . MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2. Biol Res. 2019; 52(1):18. PMC: 6448305. DOI: 10.1186/s40659-019-0219-6. View

Ma F, Zhang L, Ma L, Zhang Y, Zhang J, Guo B . MiR-361-5p inhibits glycolytic metabolism, proliferation and invasion of breast cancer by targeting FGFR1 and MMP-1. J Exp Clin Cancer Res. 2017; 36(1):158. PMC: 5683540. DOI: 10.1186/s13046-017-0630-1. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Calin G, Croce C . MicroRNA signatures in human cancers. Nat Rev Cancer. 2006; 6(11):857-66. DOI: 10.1038/nrc1997. View

Gadducci A, Sergiampietri C, Lanfredini N, Guiggi I . Micro-RNAs and ovarian cancer: the state of art and perspectives of clinical research. Gynecol Endocrinol. 2014; 30(4):266-71. DOI: 10.3109/09513590.2013.871525. View

Guo L, Pu Y, Han Z, Liu T, Li Y, Liu M . MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009; 276(19):5537-46. DOI: 10.1111/j.1742-4658.2009.07237.x. View

10.

Rehei A, Zhang L, Fu Y, Mu W, Yang D, Liu Y . MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol Sci. 2018; 22(16):5156-5164. DOI: 10.26355/eurrev_201808_15711. View

11.

Xie P . TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013; 8(1):7. PMC: 3697994. DOI: 10.1186/1750-2187-8-7. View

12.

Lim L, Lau N, Garrett-Engele P, Grimson A, Schelter J, Castle J . Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005; 433(7027):769-73. DOI: 10.1038/nature03315. View

13.

Yi Z, Lin W, Stunz L, Bishop G . Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev. 2014; 25(2):147-56. PMC: 3999169. DOI: 10.1016/j.cytogfr.2013.12.002. View

14.

Oganesyan G, Saha S, Guo B, He J, Shahangian A, Zarnegar B . Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature. 2005; 439(7073):208-11. DOI: 10.1038/nature04374. View

15.

Zhu L, Fang J . The Structure and Clinical Roles of MicroRNA in Colorectal Cancer. Gastroenterol Res Pract. 2017; 2016:1360348. PMC: 5225333. DOI: 10.1155/2016/1360348. View

16.

Hacker H, Tseng P, Karin M . Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol. 2011; 11(7):457-68. DOI: 10.1038/nri2998. View

17.

Ma J, Jing X, Chen Z, Duan Z, Zhang Y . MiR-361-5p decreases the tumorigenicity of epithelial ovarian cancer cells by targeting at RPL22L1 and c-Met signaling. Int J Clin Exp Pathol. 2020; 11(5):2588-2596. PMC: 6958233. View

18.

Cui W, Li Y, Xu K, Chen G, Lu X, Duan Q . miR-361-5p inhibits hepatocellular carcinoma cell proliferation and invasion by targeting VEGFA. Biochem Biophys Res Commun. 2016; 479(4):901-906. DOI: 10.1016/j.bbrc.2016.09.076. View

19.

Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang J . miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 2016; 16(1):806. PMC: 5069781. DOI: 10.1186/s12885-016-2801-4. View

20.

Wei J, Zhang L, Li J, Zhu S, Tai M, Mason C . MicroRNA-205 promotes cell invasion by repressing TCF21 in human ovarian cancer. J Ovarian Res. 2017; 10(1):33. PMC: 5420089. DOI: 10.1186/s13048-017-0328-1. View